Figure 5.
NPY1R Receptor antagonist (BIBP-3222) significantly reduced serum IL-6 in T-cell transfer colitis model. RAG1 knockout mice were injected with 0.5 × 106 CD45RB+ high T cells intraperitoneally (day 1). On day 2, the mice received the first dose of NPY Y1 (BIBP-3222) or NPY2R (BIIE-0246) antagonists via intracolonic injections (after isoflurane anesthesia), after which the mice received NPY antagonists once a week up to week 8. At the end of 8 weeks, mice were killed humanely, and serum was collected for evaluation of inflammatory markers. Serum levels of (A) TNF, (B) IL-6, (C) IL-5, (D) IL-1β, (E) KC, (F) IL-10, (G) IFN-γ, and (H) colonic NPY2R:NPY1R ratio. Values are mean ± SEM, n = 5-6. One-way ANOVA followed by Dunnett multiple comparison test. Significant differences compared with the colitic group expressed as *P < .05, **P < .01, ***P < .001.